The potential to establish dual retroviral infections was investigated in this study. Groups of macaques infected with human immunodeficiency virus type 2 (HIV-2) isolate (either GB122 or CDC77618) were exposed to the other virus at 2, 4, 8, 12, 14, or 72 weeks after primary inoculation. Dual infections were established in macaques simultaneously exposed to both viruses. In other groups, secondary infections were observed only if challenge occurred at early intervals after primary infection but before a full seroconversion. Polymerase chain reaction and virus-isolation data demonstrated that challenges at 8, 12, 14, or 72 weeks after infection with the initial isolate failed to result in a dual infection. Anti-HIV-2 serologic titers, CD4 levels, virus burden, and the ability to superinfect peripheral blood mononuclear cells in vitro were not correlated with susceptibility to or protection from secondary challenges in this investigation. These findings demonstrate a window period for susceptibility to dual infection and indicate that protection from retroviral infection may be achievable.
Identification of a Window Period for Susceptibility to Dual Infection with Two Distinct Human Immunodeficiency Virus Type 2 Isolates in a Macaca nemestrina (Pig-tailed Macaque) Model
confirmed the existence of mosaic viruses containing genetic regions from two distinct HIV-1 subtypes [14] [15] [16] [17] [18] . It has been hypothesized that these mosaic viruses have arisen by successful viral recombination events resulting from mixed infections within a single individual. Mixed infections with both HIV-1 and HIV-2 have been documented in regions, such as Côte d'Ivoire, in which both strains are prevalent [19] [20] [21] [22] , although recombination among these virus types has not been reported. Data from in vivo viral challenge experiments using HIV-1-infected chimpanzees, simian immunodeficiency virus (SIV)-infected macaques, and HIV-2-infected baboons suggest that dual infections can be established under certain conditions in each of these animal model systems [23] [24] [25] [26] . However, the opportunity for dual infections to occur and the susceptibility of an individual to a secondary retrovirus exposure is not well understood.
To address these issues, we used the HIV-2 pig-tailed macaque model of human retroviral infection, which provides a controlled environment for evaluation of retrovirus-host interactions. Here, we used two genotypically distinct HIV-2 subtype A strains: a high syncytia-forming isolate from Guinea Bissau (GB122) and a highly cytolytic isolate from Cô te d'Ivoire (CDC77618) [27] . Infection of pig-tailed macaques with either isolate leads to productive viral replication, typical seroconversion, and a characteristic decline in the total CD4 ϩ cell population. In this report, we investigated the susceptibility of previously infected macaques to a dual infection by another virus challenge at different times after primary virus exposure. The information provided by our study design may have important implications for virus transmission and vaccine development.
Materials and Methods
Animals and housing. Thirty-two adult pig-tailed macaques (26 males and 6 females), aged 3-5 years and weighing 5.5-8 kg (Charles River Breeding Laboratories, Wilmington, MA), were used in this study. During a quarantine period of 60 days prior to viral inoculation, this cohort was tested for active malaria, tuberculosis, SIV, simian retrovirus type D, Cercopithecine herpes virus 1 (B virus), HIV-1, and HIV-2. Results for all of these agents were initially negative for all animals. These outbred animals were housed individually under biosafety level-3 containment conditions.
Viruses: in vitro replication, in vivo inoculations, and isolations. HIV-2 strains GB122 and CDC77618 are primary field isolates that were obtained from AIDS patients residing in Bissau, Guinea Bissau, and Abidjan, Cô te d'Ivoire, respectively. In each case, virus was isolated from cocultures by use of primary activated human peripheral blood mononuclear cells (PBMC) as target cells. Subsequent passage on either human or pig-tailed macaque PBMC was minimized, to retain the original viral phenotype and genotype. In brief, cell-free virus stocks were standardized on the basis of core antigen titers (Coulter, Hialeah, FL), and equivalent amounts of cell-free material (5 ng) were passaged onto parallel cultures of human and pig-tailed macaque (heterologous pool from 4 consistent donor animals) PBMC. After an overnight incubation at 37ЊC, 5% CO 2 , the cells were washed and resuspended in standard growth medium at a final cell concentration of ∼ per mL, as detailed 6 2 ϫ 10 elsewhere [27, 28] . Cultures were followed for 14 days and fed once at day 7 by use of activated PBMC freshly stimulated with phytohemagglutinin (PHA, GIBCO Laboratories, Grand Island, NY). The production of core antigen was monitored as a parameter of infection and replication for each strain [29] .
In vivo challenge stocks for each wild-type virus consisted of macaque PBMC from the bulk culture combined with ∼10 4 6 6 ϫ 10 TCID/mL of supernatant. The cell-free component of this mixture corresponded to at least 10 2 pig-tailed macaque infectious doses (MID) as assessed by in vivo titration experiments and was approaching 10 3 MID when combined with the cell-associated component of the inoculum. All viral exposures occurred through the intravenous (iv) route.
PBMC specimens were collected from inoculated animals and processed by standard methods [27, 28] . Single-cell suspensions of various tissues harvested from these animals were prepared by routine cell-sieving procedures, enumerated, and used to generate direct cell lysates for polymerase chain reaction (PCR). The remaining cells were either cocultured for virus isolation or cryopreserved. The presence of intracellular provirus, the production of core antigen, and the production of infectious progeny virus were all monitored as parameters of infection and replication for each attempted virus isolation. Infectious cellular titers were obtained by standard coculturing techniques [30, 31] .
Phylogenetic analysis. The genetic relationship of our prototypic HIV-2 isolates was established by the neighbor-joining method in the Phylip 3.5c package (University of Washington, Seattle) and was confirmed by use of maximum-likelihood analysis with the fasDNAml program. A variety of HIV-2 and SIV gene sequences were included in this analysis, for comparative purposes. SIV-chimpanzee was used as the outgroup for each analysis.
Strain-specific detection in circulating PBMC and tissue specimens. The sensitivity (12 copies per 1 mg background macaque or human DNA) and high specificity of our HIV-1 and HIV-2 proviral DNA-PCR assays has been detailed elsewhere [21, 27] . Detection of HIV-2 provirus in this study was accomplished by adaptation of this previously described methodology to a standard two-step HotStart PCR protocol using AmpliWax (Perkin-Elmer Cetus, Norwalk, CT) as a barrier. In brief, the slight modification of our existing protocol included use of a solution of 10 mM Tris, pH 7.5, and 0.1% Triton-X 100 reagent (Fisher Scientific, Pittsburgh) to prepare cell lysates at PBMC per mL. After 6 4 ϫ 10 washed cells were resuspended in this lysis reagent, all samples were treated with proteinase K (100 mg/mL final concentration; Boehringer Mannheim, Indianapolis) at 56ЊC for 1 h. After inactivation of proteinase K at 95ЊC for 15 minutes, PCR was used to amplify various HIV target regions: 2 cycles of a 1-minute denaturation at 98ЊC coupled with a 1-minute primer annealing/elongation at 65ЊC, followed by 38 cycles of a 30-s denaturation at 94ЊC coupled with a 1-minute annealing/elongation step at 60ЊC and a final extension of 5 minutes at 72ЊC. Standard protease primers used in this study were DP26a: 5 -CACCTCAATTCTCTCTTTGGA-3 (nucleotide position, 2082-2102) and DP27: 5 -TAGATTTAATGACATG-CCTAA-3 (nucleotide position, 2360-2380).
To distinguish the HIV-2 strains detailed in this report, all generated PCR amplicons were mapped with a panel of restriction endonucleases (Gibco and New England BioLabs, Beverly, MA) for predicted digestion patterns. Polyacrylamide gels (NOVEX, San Diego, CA), both 10% and 12%, were used for analysis of restriction fragment length polymorphisms (RFLPs). The resulting fragments were transferred to nylon membranes and analyzed by use of a consensus protease probe [21] by nonradioactive Southern blotting methodologies (Amersham Laboratories, Arlington Heights, IL).
A commercially available PCR ELISA system (Boehringer Mannheim) for efficient, semiquantitative detection of PCR amplicons was also adapted to distinguish molecularly distinct HIV-2 strains, for confirmation purposes.
In brief, PCR amplifications were performed in the presence of digoxigenin (DIG)-dUTP according to the manufacturer's protocol. The resulting amplicons were denatured, hybridized to biotinylated virus-specific oligonucleotide probes, and captured onto streptavidin-coated microtiter wells. Bound hybrids were detected by use of an anti-DIG peroxidase conjugate with an appropriate colorimetric substrate. GB122-specific protease probe (95RO2) sequences, 5 -ATGCGATTATAGCCCAAAAA-3 (nucleotide position, 2200-2219), and CDC77618-specific protease probe (95RO3) sequences, 5 -AAGTACTAAATAAAAGAGTAAGA-3 (nucleotide position, 2276-2299), were biotinylated during synthesis by standard techniques.
Confirmatory nested PCR reactions to amplify HIV-2 protease proviral sequences were done with 2 mL of a 100-mL primary PCR reaction product under the same conditions described above. The outer primers used for these amplifications were DP20: 5 -GA-CAGAGGACTTGCTGCA-3 (nucleotide position, 2068-2083) and DP21: 5 -GGCCATTGTCTCAGTTTTGG-3 (nucleotide position, 2435-2454). In this case, the standard protease primers (DP26a and DP27) were used as the inner set during the nested reactions.
Serology and lymphocyte phenotyping. HIV-2 serologic analysis was performed by use of whole-virus lysate EIA (Genetic Systems, Seattle) and Western blotting techniques (Epitope, Beaverton, OR). Seroreactive titers were determined by means of a standard 2-fold dilution series and analysis of the lowest reactive dilution by EIA. Serum neutralization assays were performed as described by Lohman et al. [30] with the following modifications: the PM-1 cell line was used as a target for virus infection and replication, and culture supernatants were collected after 7 days. A defined panel of cellphenotyping reagents was used to characterize and monitor pigtailed macaque lymphocyte populations during the course of infection, as detailed elsewhere [27, 32, 33] . Cells from whole blood with EDTA used as the anticoagulant were stained with fluorescein-5-isothiocyanate-or phycoerythrin-conjugated mouse anti-human cell monoclonal antibodies commercially available from Becton Dickinson (Mountain View, CA). A Becton Dickinson FACScan flow cytometer was used to analyze all stained samples.
In vitro dual infections. Isolated PBMC specimens from HIV-2 strain GB122-infected animals, prior to any in vivo secondary virus challenge, were seeded into 24-well plates at cells/mL, 6 1 ϫ 10 PHA-stimulated for 72 h, and either exposed to standardized amounts of HIV-2 strain CDC77618 (corresponding to ∼MOI of 0.1) or mock-infected with normal growth media. After an overnight incubation, the cells were washed, resuspended in growth media, and cultured for 14 days. Exchanges of growth media occurred on days 4 and 10, whereas a single feed of PHA-stimulated autologous cells (again from day 0 of in vivo challenge) was given on day 7. Core antigen production by these PBMC cultures was used as an indicator of virus infection and replication. DNA-PCR analysis of cell lysates and amplicon endonuclease digestion patterns, as outlined above, were used to determine the HIV-2 strain profile of each culture.
Results

Molecular distinction and genetic relatedness of HIV-2 isolates.
DNA-PCR amplification of conserved HIV-2 proviral protease gene sequences served as a highly sensitive molecular detection strategy for the establishment of infection in this study. Differential amplicon RFLP patterns were compared with established isolate-specific standards, yielding the expected protease signature pattern for interpretation (figure 1). This assay has a lower limit of detection in the range of 2-10 proviral copies per 100,000 macaque PBMC (or ∼1 mg of background macaque DNA per reaction). GB122-specific and CDC77618-specific probes were also developed and shown to detect the respective HIV-2 strain exclusively (data not shown). Both virus strain-specific detection systems have been incorporated into a routine monitoring strategy of direct PBMC and tissue specimens, as well as primary diagnostic cultures originating from our macaque cohort. Mixing experiments using known amounts of cloned, strain-specific protease DNA demonstrated that both methods were capable of detecting low levels of either primary inoculating or secondary challenge provirus in the presence of up to 1000-fold higher quantity of the opposing strain (data not shown). Readily detectable, virus-specific PCR signals were also observed by use of various titrated mixtures of cell lysate material derived from macaques individually infected with each HIV-2 isolate (data not shown).
Genetically, GB122 and CDC77618 are distinct from SIV strains, as well as from each other, as indicated by differences in the extremely conserved protease gene (figure 2), with a diversity of 12% at the nucleotide level between these HIV-2 isolates. Both viruses phylogenetically cluster with other typical West African HIV-2 subtype A viruses. This pattern was maintained upon further examination of the more variable env-transmembrane region (not shown) and env-V3 gene regions [34] , with nucleotide diversity of 16% and 20%, respectively.
In vitro replicative potential and in vivo infectiousness of HIV-2 isolates. GB122 and CDC77618 were able to initiate and maintain productive replication in pig-tailed macaque PBMC in vitro. As shown in figure 3, replication kinetics for both HIV-2 isolates in pig-tailed PBMC were comparable, and peak virus replication occurred at day 11. We observed similar kinetics using human PBMC as targets of viral replication, although peak replication was generally 2-3 times higher for both viral strains (data not shown).
The animal challenge stocks of GB122 and CDC77618 derived for this study were highly infectious for pig-tailed macaques. In vivo evidence of productive viral infections in 3 representative animals for each strain during the initial 12 weeks after inoculation is summarized in table 1. As we reported elsewhere for GB122 [27] and outlined here for CDC77618, iv exposure to these strains leads to persistent, systemic infections and resulted in a typical seroconversion profile beginning at week 3 postinoculation in every inoculated animal. We observed a 125% decline in the total CD4 ϩ cell population in 2 of the 3 GB122-infected animals and in 1 of the CDC77618-infected animals. Inversion of CD4/8 ratios in biopsied inguinal lymph node samples from these animals was also observed (data not shown). Proviral burdens (range, 200-125,000 copies per 10 6 PBMC) and cell-associated viral burdens (range, 10-2000 TCID per 10 6 PBMC) were not appreciably different between GB122-and CDC77618-infected animals through the first 12 weeks PI.
In vivo viral challenges and analysis after secondary exposure. To investigate the susceptibility of HIV-2-infected pigtailed macaques to a dual infection, 18 available animals previously infected with either GB122 or CDC77618 were exposed iv to the opposing strain. Groups of animals were stratified according to the timing of secondary virus exposure. As presented in table 2, virus-specific serologic titers and circulating CD4 ϩ and CD8 ϩ cell levels varied at the time of secondary challenge among the cohort under study, consistent with our previous observations with HIV-2-infected pig-tailed macaques [27] .
In two naïve animals inoculated simultaneously with both HIV-2 strains, mixed infections were readily evident at all time points after exposure (table 3) . Direct PCR analysis of circu- Figure 1 . Human immunodeficiency virus type 2 (HIV-2) strain-specific signature patterns. Targeted protease gene sequences were amplified and subjected to endonuclease digestion with a defined panel of enzymes followed by separation on a 10% polyacrylamide gel. After Southern blot transfer of amplified products to nylon membranes, HIV-2-specific oligonucleotide hybridization techniques were used to visualize resulting amplified products and to interpret the isolate-specific restriction patterns. A, Diagnostic restriction enzyme digestion patterns for standard amounts (100 copies) of cloned protease genes in the context of macaque peripheral blood mononuclear cell background lysate that represents GB122 and CDC77618 proviral DNA. B, Expected proviral protease signature patterns derived by restriction fragment length polymorphism analysis; * denotes reactivity with a standard, consensus HIV-2 oligonucleotide probe. For AluI-digested GB122, the minor probe-reactive fragment (110 bp) was not routinely used for virus-typing purposes because of the gel type and standard running times consistently used for separation of larger fragments.
lating PBMC, as well as virus isolation techniques, clearly showed the presence of both HIV-2 strains in these animals. Each animal seroconverted by week 3 and sustained severe losses of CD4 ϩ lymphocytes (150% depletion), as described elsewhere for this macaque species [27, 35] .
The 18 animals previously exposed to a single HIV-2 strain were all clearly harboring their original primary inoculating strain within the circulating PBMC compartment at week 0 of challenge. In addition to those exposed simultaneously to both viruses, animals challenged early in their primary infections (4/ 4 at week 2 and 1/4 at week 4) were susceptible to HIV-2 dual infection (table 3) . Surprisingly, only primary provirus was repeatedly detectable after secondary challenge in 3 of 4 animals from the week 4 group and in all 10 animals challenged at у8 weeks after primary inoculation (table 3) . Virus isolation attempts from freshly isolated macaque PBMC (at least 10 7 ) were performed at monthly intervals to allow in vitro amplification and detection of any secondary challenge virus being harbored at low levels. PCR analyses of these representative diagnostic PBMC cultures were identical to those results obtained from direct PBMC, which indicated a protection from the establishment of dual infection in all 13 animals. At ∼24 weeks after challenge, inguinal lymph nodes were biopsied from selected animals from which only the primary inoculating stain was detected in PBMC, to determine whether the secondary challenge strain was sequestered. Direct proviral PCR analysis of these harvested tissues confirmed the absence of secondary challenge virus observed in the peripheral blood (table 3) . Diagnostic culture results, set up with isolated cells from these lymph node tissues and with primary human PBMC used as target cells, were identical to these direct PCR findings. Additional lymphoid tissues (axillary lymph node, mesenteric lymph node, gut-associated tissue, and spleen) were collected at scheduled necropsies from 2 animals, mac72-38 and mac72-244, and after the AIDS-related deaths of mac22-220 and mac22-174. All viral detection assays for these direct tissue specimens and resulting culture samples confirmed the exclusive presence of the primary inoculating strain in these animals. Nested PCR amplifications for proviruses, followed by RFLP analysis performed on all direct tissue specimens collected and on direct PBMC lysates from an early and a late time point after secondary virus exposure, verified the primary PCR results in all cases (data not shown). In addition, primary proviral and cell-associated viral burden data at the time of challenge demonstrated no predictive trend related to the observed protection or clearance observed in this study (data not shown).
As a mock-infected challenge control for this study, the protective ability of the original heterologous pool of uninfected macaque cells, used for generating both viral stocks, was examined. Four animals were inoculated with PHA-activated, uninfected macaque PBMC and virus-free culture supernatant. In sets of 2, these experimental animals were subsequently challenged at 12 weeks with either the cell-free GB122 macaque PBMC stock (10 4 TCID) or a cell-free GB122 human PBMC stock of identical titer. All 4 test animals became infected, demonstrating no protective effects from acute HIV-2 replication, with accompanying serologic and hematologic features indistinguishable from those of parallel naïve infection control animals (data not shown).
Changes in serologic and hematologic parameters after secondary virus exposure. To determine whether the apparent protection from the establishment of dual infections coincided with increases in humoral antibody responses, titers were measured and compared during the first month after secondary virus exposure. Detectable seroconversion as a result of viral exposure begins at week 3 in this macaque species, as a result of HIV-2 infection (table 1). Depending on the individual animal, the average peak titer usually occurs between weeks 8 and 24 after inoculation, and serologic data from all pig-tailed macaques in this study were consistent with these general values. Interestingly, fluctuations in antibody titers observed in the 14 primary seropositive macaques during their initial 4 weeks animal at week 3 after infection; at least 3 independent draws at weekly intervals prior to any experimental inoculation were used to set the baseline hematologic value.
after secondary challenge were 0-fold in 3 animals (macs22-174, 82-76, and 22-220), 2-fold in 5 animals (macs83-296, 83-298, 22-204, 72-38, and 22-221), 4-fold in 4 animals (macs83-271, 83-290, 22-202, and 53-421), 8-fold in 1 animal (mac72-248), and 32-fold in 1 animal (mac72-244) with no apparent trend correlating with resistance to dual infection. Although the notable increases were intriguing, these inconsistent seroresponses could be anamnestic in nature, which would not be surprising, given the amount, makeup, and iv delivery of the challenge inoculum. Furthermore, virus-neutralizing antibody titers determined from representative animals at the time of challenge did not correlate with the apparent protective effects observed (data not shown). In addition, the observed lack of dual infection in the group of 13 resistant animals could not be attributed to the absence of circulating CD4 ϩ T lymphocytes at the time of inoculation (table 2) . Likewise, perturbations in either the CD4 ϩ or CD8 ϩ cell populations prior to secondary challenge and those observed р1 month after the challenge exposure (figure 4) were not significantly correlated with the resistance (13 animals) or susceptibility (5 animals) to dual infections ( for CD4 ϩ P ϭ .638 and for CD8 ϩ ). The mean percents change during the P ϭ .102 first month after secondary challenge in the CD4 ϩ cell population among the resistant group versus the susceptible group of animals were ϩ1.8% and Ϫ1%, respectively. Interestingly, the mean percent change during the same time frame in CD8 ϩ cells was higher (approaching ϩ10%) in the group susceptible to dual infections than in the resistant group as a whole (ϩ2.5%).
In vitro infection of PBMC isolated from HIV-2-infected pigtailed macaques.
To directly assess the susceptibility of HIV-2-infected PBMC to another retrovirus infection, PBMC specimens obtained from strain GB122-infected animals on day 0 of secondary virus challenge were exposed to strain CDC77618 in vitro. In all cases (figure 5), core antigen-production levels during the following 14 days were higher in CDC77618-exposed test cultures than in mock-infected cultures (included as a control for replication of the original infecting virus, GB122). The kinetics of CDC77618 replication in cultures derived from GB122-infected animals were comparable to those of replication in uninfected control macaque PBMC, further indicating the establishment of in vitro dual infections. Molecular typing of cell-associated virus by DNA-PCR using cell culture lysates verified in vitro dual infection in all test cases (figure 5). The presence of CD8 ϩ cells derived from the GB122-infected macaques did not affect the ability to establish dual infections in whole, activated PBMC from these animals in vitro. However, the replicative ability and culture isolation of the original infecting GB122 virus was dramatically enhanced by depletion of CD8 ϩ cells prior to culture initiation (data not shown).
Discussion
In this study, timing of secondary virus exposure was a critical factor in the observed susceptibility to or apparent protection from a dual retroviral infection. The findings presented identify for the first time an early time frame, during a primary infection, for extreme susceptibility to the establishment of a dual infection. This susceptibility was followed by a period in which dramatic resistance to retroviral challenge was observed. Specifically, productive mixed HIV-2 infections were established in pig-tailed macaques by simultaneous in vivo exposures. Dual infections were also observed if viral challenge occurred at an early time interval (week 2 or 4) after primary infection. All animals exposed at у8 weeks after primary inoculation resisted the establishment of a secondary retroviral infection. Highly of secondary virus challenge; at least 3 independent draws at weekly intervals prior to any experimental inoculation were used to set the baseline hematologic value.
reliable and reproducible data regarding the presence of both HIV-2 strains was generated by use of various methods shown to readily detect dual infections established in vitro, in vivo, and in reconstructed specimens. The inability to detect any secondary challenge virus in either peripheral blood or selected lymphoid compartments by sensitive molecular detection and tissue culture techniques suggests that, in this model, protection from a subsequent virus exposure was achieved. Selective depletion of the total CD4 ϩ cell population is a consequence of HIV-2 infection in pig-tailed macaques, similar to that for HIV-1 or HIV-2 infection in humans [27, 31, 35, 36] . However, the lack of observable dual infection in HIV-2-infected animals documented in this report occurred irrespective of CD4 ϩ cell status. Macaques 22-220 and 22-221 were chosen specifically for attempted secondary virus challenges because of their relatively normal levels of circulating CD4 ϩ cells available as targets for secondary infection. In the absence of normal CD4 ϩ cell levels, pig-tailed macaques (e.g., 22-202, 22-174, and 82-76) exposed to another challenging strain were also resistant to the establishment of this secondary viral infection at 8 weeks or after postprimary infection.
Studies in vitro have suggested that superinfection of infected cells can be difficult [6, 7] . A possible mechanistic explanation for these observations involves a downregulation of susceptible CD4-receptor binding sites or other coreceptors on primary infected target cells, thus limiting or blocking access of challenging virus into a previously infected cell. However, attempted in vitro infections of PBMC samples isolated on the day of in vivo challenge from representative HIV-2-infected macaques demonstrating resistance to secondary infections in vivo were successful. These findings, coupled with the in vivo availability of CD4 ϩ cell populations at the time of secondary virus exposure in protected animals, suggested that their peripheral blood contained sufficient targets for the establishment of a dual HIV-2 infection.
In addition, potential coreceptor use by either the primary or challenging virus does not account for the in vivo susceptibility of animals to dual infections noted in this report. Although marked differences have been observed in vitro between GB122 (high syncytial activity) and CDC77618 (extremely cytolytic), both human and pig-tailed macaque T helper cell and monocyte populations were susceptible to infection by each HIV-2 isolate (R. A. Otten, unpublished results). These observations were consistent with a recent report by Owen et al. [34] documenting that these HIV-2 strains, unlike many SIVs, are able to use a variety of coreceptors, including CCR5, CXCR4, CCR2b, CCR3, and BOB.
The exact mechanism of protection observed in all animals exposed to the challenging HIV-2 strain у8 weeks after primary inoculation and in 3 animals (of 4) at 4 weeks after primary infection in this study is not clear. Previous studies have documented absolute protection from SIV infection by uninfected human cells [37, 38] . Subsequent investigations revealed that immune reactivity directed against human class II HLA-DR could protect against challenge from virus propagated on human cells expressing this molecule, but not macaque cells containing allotypic determinants [39] . Experiments in our study were designed to assess any protective contribution of determinants present on the heterologous macaque cells used to propagate both challenge stocks. All test animals inoculated with heterologous cells 12 weeks before a cell-free viral challenge demonstrated acute HIV-2 replication with accompanying serologic and hematologic features indistinguishable from those of naïve controls. Thus, the protective effects reported in this study were not due to induced responses targeting cellular components on the surface of activated cells or exposed on the virus membrane. Furthermore, virus-specific neutralizing antibody levels obtained from representative animals at the time of secondary challenge did not predict the outcome, a finding consistent with other data that failed to support a major role for neutralizing antibody responses in protective immunity [reviewed in 40].
In numerous live-virus challenge studies using SIVs, HIV-2s, and simian HIV (SHIV) constructs, the in vivo replicative nature of the primary inoculating strain has been a key issue for inducing a protective effect [30, 31, [41] [42] [43] [44] [45] [46] [47] [48] [49] . In general, the degrees of protection observed depended on the replicative level of the primary inoculating strain. High-versus low-dose primary inoculations, in addition to the makeup of the original inoculum, have also been shown to affect the outcome of a particular challenge exposure [31] . The degree of viral attenuation necessary to induce protective effects, while remaining benign in the host, has been controversial and has not yet been clearly elucidated. This remains a critical issue in the search for a vaccine capable of eliciting protective immunity. In addition, it has been suggested that the length of time (as much as 18 months) between primary inoculation and subsequent challenge in the attenuated vaccine models can be associated with better protection from pathogenic SIV [49, 50] . However, further evidence suggested that protection could be achieved at an even earlier time interval, within 4-8 months [42] . For our study, primary inocula in all cases consisted of nonattenuated, livevirus preparations that were able to readily establish productive infections of previously naive animals. This full functionality of the primary virus may account for the relatively rapid induction of protective effects observed in this study.
Whatever the protective correlate, a strong clearance mechanism was apparent to prevent the establishment of dual infections after a large-dose iv exposure, which was surprising, given the nature of an inoculum designed to readily establish productive dual infections. There was no question that all macaques receiving the challenge inoculum, consisting of productively infected cells and infectious cell-free virus, could be considered infected because of the nature of the exposure. In fact, elevated antibody levels, observed in some challenged macaques, indicated possible recognition (anamnestic responses) of common epitopes elicited by this secondary exposure. The main issue was the observed ability of certain macaques to resist the establishment of a chronic dual infection and apparently eliminate all indications of the secondary challenge virus. Al- ϩ and CD8 ϩ cell populations among the observed 13 dual infection-resistant versus 5 susceptible macaques within the first month after secondary viral challenge. Results are reported as the change among percent baseline values for both CD4 ϩ and CD8 ϩ cell levels from weeks 0-4 after challenge (for specific percent baseline levels at the time of challenge refer to table 2). though nonspecific clearance mechanisms may be responsible for this elimination, the timing of protective effects documented in this report suggests a maturation of an immune-based mechanism of clearance. If this is the case, it is highly likely that immune-cell mediation was at least partially responsible for the protection. The contribution of soluble or cell-associated virussuppressor effects of CD8 ϩ cells has not been examined in the HIV-2 pig-tailed macaque model and may be warranted on the basis of the avid ability of this cell population to suppress virus replication in vitro and to resist seeding of peripheral lymphoid sites (R. A. Otten, unpublished observation). Recent studies with HIV-2-infected baboons and SHIV-infected rhesus macaques document an active role of this cell population in controlling the acute phase of virus replication both in vitro and in vivo [51, 52] .
In view of recent observations by Walker et al. [53] , determination of the contribution of induced helper T cell responses toward protective effects in these animals may have merit. It is also very plausible that host interactions with an actively replicating primary virus may be necessary, to induce the appropriate antiviral mechanisms needed for clearance of a challenging virus. For instance, antibody-dependent cell-mediated cytotoxicity responses (reviewed in 54) alone or in concert with other mediators of host defense initially stimulated by the primary inoculum and reactivated in response to the challenge virus has not been fully appreciated and may contribute toward the protection from the secondary virus challenge outlined here. Although there was no obvious correlation of serotiters with protection from dual infection, other, more subtle serologic parameters involving conformational dependence or avidity may contribute to a critical immune response maturation as detailed by Cole et al. [55] . Quality rather than quantity may be important factors in the effectiveness of the early humoral response mounted against the virus. Therefore, study designs to investigate differences among antibody populations in a longitudinal manner after exposure may be required, to fully assess any contribution toward protection.
Clinical follow-up and further challenges are ongoing in the remaining 7 of 13 resistant animals. No evidence of secondary challenge virus was evident upon testing every 6 months up to 3 years after challenge, although these remaining animals are at different stages of immunosuppression because of hallmark losses of CD4 ϩ cells as a result of their primary infection. Death associated with AIDS-related immunosuppression caused by the primary HIV-2 infection has been observed in 4 of the 13 resistant animals, 2 of which were necropsied for tissues. Only 4 of 7 dually infected animals remain alive, whereas the others succumbed to their infections. Of interest, the mean time to death differed ( ) between those animals protected from P ϭ .184 mixed infections (4 years) and those who were susceptible (2.4 years). Although the number of animals per group is small (3 each), this observation may reflect a synergistic effect of both viruses toward disease progression in this macaque species. It is also tempting to speculate that virus recombination may occur in animals that harbor mixed infections, leading to mosaic genomic sequences. There are preliminary indications of in vivo virus selection in two dually infected animals, resulting in increased virulence, possibly through recombination, as indicated by rapid onset of illness in this macaque species. Further studies to elucidate these issues are ongoing.
In summary, HIV-2 dual infections can be established if a secondary exposure occurs within an early window period of susceptibility after a primary exposure. On the basis of these findings, persons in high-risk populations who have the potential for multiple exposures within a short time span may be at increased risk for a mixed infection. Once established, these mixed infections could be readily transmissible because of the simultaneous nature of the exposure, such as in a case recently reported by Janini et al. [55] . The potential for dual transmission would also likely depend on virus levels present at mucosal sites of each distinct subtype at the time of exposure. These occurrences provide a setting for exchange of genomic material among distinct viruses through recombinational mechanisms, possibly resulting in increased fitness (e.g., drug resistance) that Figure 5 . In vitro infection of peripheral blood mononuclear cells (PBMC) isolated from representative human immunodeficiency virus type 2 (HIV-2) GB122-infected animals on day 0 of in vivo virus challenge. Test, PBMC cultures exposed to standardized amounts of HIV-2 strain CDC77618 (corresponding to ∼MOI of 0.1); Mock, parallel cultures mock-infected with normal growth media. The levels of core antigen production through 14 days of culture are indicated, and these values represent the average obtained from duplicate cultures. Strain-specific polymerase chain reaction (PCR) profiles were obtained by generating PBMC lysates from the cultures at the times indicated for DNA-PCR of the protease region followed by amplicon digestion with standard endonucleases, yielding HIV-2 strain-specific signature patterns as outlined in Materials and Methods. 122, detection of only strain GB122; 618, detection of only strain CDC77618; Dual, detection of both strains; neg, negative PCR findings; and nt, those time points not tested. PBMC specimens obtained from HIV-2 seronegative macaque 72-79 were used as the positive control for virus infection and replication caused by strain CDC77618 and as the negative control for mock infections with growth media.
could have a marked impact on the overall epidemic. Apparent protective effects, as a consequence of virus exclusion or immune-based recognition, have also been observed in this study. Taken together, these findings may partially explain the paradox of how documented instances of both dual infections and apparent protection from secondary virus challenges can exist in humans.
